Cite
APA Citation
Tariq, B., Ou, Y. C., Stern, J. C., Mundra, V., Wong Doo, N., Walker, P., Lewis, K. L., Lin, C., Novotny, W., Sahasranaman, S., & Opat, S. (2023). a phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & lymphoma, 64(2), 329–338. http://access.bl.uk/ark:/81055/vdc_100179399972.0x000039